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Introduction
Lectures were mainly on the genetics of complex osteoar-
ticular disorders, and were grouped in such a way as to
build a foundation of knowledge on the two selected
topics. The meeting was attended by 120 Italian endocri-
nologists, rheumatologists, geriatricians, radiologists,
general practitioners and postdoctoral researchers.
The first session dealt with both general and specific
aspects of quantitative genetics of OP and OA. It also
included presentations of polymorphisms of VDR and
COLIA1 genes and their corresponding functional vari-
ants. The second session introduced an interesting
concept, the estrogen response in the genetics of OP,
and then focused on genetic aspects of male and familial
OP, concluding with the role of Fos proteins in bone
pathophysiology in mice. The third session was on the
pathophysiology of OA, the genetics of primary general-
ized OA and familial osteochondrodysplasias. An interest-
ing perspective on the future role of pharmacogenomics in
osteoarticular disorders concluded the meeting.
This report is organized into eight distinct topics; it will
focus on general genetic concepts and study models and
new perspectives for approaching these complex diseases.
The concepts and arguments presented in each topic area
are common to all of the speakers in each section, except
where the speakers are individually named.
Osteoporosis (OP) and osteoarthritis (OA), the two most common age-related chronic disorders of
articular joints and skeleton, represent a major public health problem in most developed countries.
They are influenced by environmental factors and exhibit a strong genetic component. Large population
studies clearly show their inverse relationship; therefore, an accurate analysis of the genetic bases of
one of these two diseases may provide data of interest for the other disorder. The discovery of risk and
protective genes for OP and OA promises to revolutionize strategies for diagnosing and treating these
disorders. The primary goal of this symposium was to bring together scientists and clinicians working
on OP and OA in order to identify the most promising and collaborative approaches for the coming
decade. This meeting put into focus the importance of an adequate genetic approach to several areas
of research: the search for the genetic determinants underlying new susceptibilities, the optimization of
previously acquired data; the establishment of correlations between genetic polymorphism and
functional variants, and gene–gene and gene–environment interactions (particularly those between
genes and nutrients). An adequate genetic approach is also essential with regard to determining more
selective criteria for phenotypic definition of familial OP, in order to obtain more homogeneous and
statistically powerful family-based studies. The symposium concluded with an interesting overview of
the future perspectives offered by DNA microarray technologies for identifying novel candidate genes,
for developing proteomics and bioinformatics analyses and for designing low-cost clinical trials.
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Quantitative disorders
G Novelli (University of Rome at Tor Vergata, Rome, Italy),
A Falchetti (University of Florence, Italy) and R Nuti (Uni-
versity of Siena, Italy) discussed quantitative disorders.
A Falchetti and G Novelli discussed how quantitative dis-
orders arecommon multifactorial diseases; both genetic
and environmental factors contribute to their pathogene-
sis. They exhibit a polygenic pattern of inheritance. OP
and OA represent common quantitative disorders and dif-
ficulty exists in identifying responsible genes. They are
extremely heterogeneous conditions, with contribution
from low-penetrance, common alleles and environmental
factors, often unknown or not measurable. Twin and sib-
pair studies have clearly assessed the genetic background
for both diseases. Incomplete penetrance, phenocopies,
gene interactions and other transmission mechanisms
complicate the genetic analysis.
A general approach to quantitative genetics may identify
four areas as being critical for future work, as presented
by G Novelli. The first area is what to look for and what to
expect to find. Genetic theory and modeling of popula-
tions and diseases need to be considered. It is possible
that a relatively simple genetic background exists for many
common diseases. The second area consists of stream-
lined genotyping methods, which are needed even in
centers that deal with modest numbers of samples and
polymorphisms. Centralization of high-throughput geno-
typing is recommended. Thirdly, computational tools and
methods of data analysis need to be considered and tai-
lored to make optimal use of the data sets available. The
fourth area is communication, as close interactions are
needed between clinicians and geneticists to effectively
support large-scale projects.
Genetics of osteoarthritis
The genetics of OA was discussed by T Spector (Twin
Research and Genetic Epidemiology Unit, St Thomas’ Hos-
pital, London, UK), M Matucci-Cerinic (Department of Inter-
nal Medicine, University of Florence, Italy) and O Ehtgen
(WHO Collaborating Center for Public Health Aspects of
Rheumatic Disorders and Department of Epidemiology
and Public Health, University of Liège, Belgium).
General aspects of osteoarthritis
As discussed by T Spector, no universal consensus has
been reached in defining a generalized OA phenotype.
Bone density has been found to be greater in OA patients
than in controls, years before the radiological appearance
of osteophytosis; in addition, there is a slight increase in
bone turnover during the early phase of disease [1]. A
recent study of hip OA in discordant twins [2] has sug-
gested that some of the same genes are involved in influ-
encing hip OA and bone mass. Recently, magnetic
resonance imaging data obtained from twins [3] showed
there is a genetic contribution to disk degeneration and
spinal osteophytosis. At least 50% of the variants of OA in
the hands, knees and hips are determined by genetic
factors. Association studies [4–7] exhibited positive asso-
ciations with polymorphisms of VDR,  IGF-1,  TGFβ and
COLIA1 genes, and linkage analyses strongly suggest
involvement of loci on chromosome 2q. Spector (St
Thomas’s Hospital, London, UK) suggested that a
research focus should be on intermediate phenotypes,
individually or in combination, obtained by dividing OA into
its constituent parts. They might occur independently or in
clusters determined by pleiotropic genes.
M Matucci-Cerinic spoke of how it is important to take into
account the role that environment and, specifically, nutri-
ents such as vitamins C and D may play the in reduction of
risk for disease progression and the ability of bone to
respond to injurious processes in OA. Future efforts
should be made to unravel gene–nutrient interactions, in
order to apply effective preventive measures.
Genetics of primary generalized osteoarthritis
C William’s (Division of Rheumatology, Department of Medi-
cine, Thomas Jefferson University, Philadelphia, PA, USA)
presentation focused on the genetics of generalized OA.
Subsets of OA, particularly primary generalized OA,
exhibit a pattern of inheritance. Patterns of genetic contri-
bution have been clearly demonstrated and both heritabil-
ity and relative risk have been evaluated. Whole genome
screens [7–9] pinpoint quantitative trait loci on 2q, 4q35
and 16p. Sib-pair analysis, by candidate-gene and
genome-wide screening, has been extensively applied to
the genetic dissection of primary generalized OA to over-
come incomplete penetrance of traits, phenocopies, and
environmental influences. A significant linkage was found
at the COL9A1 locus in a cohort of female pairs affected
by hip OA, but screens also implicated 2q, 11q, 4q, 6p,
16p and 7p quantitative trait loci. Association studies
failed to provide unequivocal results in differently
selected populations.
Polymorphisms of VDR and COLIA1 genes
Discussions of VDR and COLIA1 genes were presented
by AG Uitterlinden (Departments of Internal Medicine, Epi-
demiology and Biostatistics, and Clinical Chemistry
Erasmus Medical Center, Rotterdam, The Netherlands), JA
Eisman (Bone and Mineral Research Program, Garvan
Institute of Medical Research, St. Vincent’s Hospital,
Sidney, Australia) and SH Ralston (Bone Research
Group, University of Aberdeen, UK).
Presentations given by AG Uitterlinden and JA Eisman
highlighted how polymorphisms of COLIA1 and  VDR
genes, whose protein products are collagen type 1 and
the vitamin D receptor, respectively, have been extensively328
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studied in OP, but there have been conflicting results on
their association with bone fragility, intestinal calcium
absorption and bone mineral density (BMD) at various
skeletal sites [10]. The largest study published so far
(1782 Dutch elderly men and women) has obtained con-
sistent results using haplotype construction [11] of the
three 3′-end restriction fragment length polymorphisms of
VDR. Accurate recognition of allelic heterogeneity, by hap-
lotyping, is important to identify the risk alleles at this part
of the gene. Observation of substantial sequence variation
in the 3′ untranslated region suggests its influence on
VDR function [12,13]. A known single nucleotide polymor-
phism at exon 2 of VDR alters the translation start site,
thus determining two variant forms of receptor that differ
by three amino acids; however, its universal association
with BMD has not been reported. Recent findings [11,13]
not only indicate that there are multiple polymorphic varia-
tions of VDR, but also that they could have different types
of consequences. In fact, 5′ promotor variations are able
to alter mRNA expression patterns and levels, and 3′
untranslated region polymorphisms could affect mRNA
stability and most likely also VDR protein levels.
As presented by SH Ralston, functional studies of the
intronic polymorphism at the Sp1 binding site of the
COLIA1  gene, originally associated with reduction of
BMD and increased risk of osteoporotic fractures, demon-
strated that it correlates with increased binding affinity for
the transcription factor Sp1 and increased allele-specific
transcription of COLIA1 in vitro [14]. Osteoblasts from
heterozygotes produce an abnormal ratio of collagen
alpha I (1) chains relative to alpha I (2) when compared
with homozygotes. Ex vivo mechanical testing demon-
strated different bone yield strength; composition analysis
demonstrated a different inorganic content and different
heterogeneity of mineralization according to this polymor-
phism [15,16].
Thus, in an apparently single metabolic pathway, many
proteins interact and consequently the combination of
polymorphisms can be pathogenic (AG Uitterlinden and
JA Eisman). Future efforts will focus on the identification of
all polymorphisms across the VDR gene by defining the
haplotype patterns in order to better understand the
pathophysiological role that the polymorphisms them-
selves exhibit in relation to the biological parameters influ-
enced by the vitamin-D-related system. Not only does this
important pleiotropic endocrine pathway influence BMD
and BMD-independent fracture risk, but VDR  polymor-
phisms have also been associated with OA, myocardial
infarction, breast cancer, prostate cancer, diabetes and
susceptibility to infectious diseases. Thus, the VDR gene
can be a useful model for investigating some of the mech-
anisms resulting in wide-ranging allelic polymorphism
effects. It should always be taken into consideration,
however, that some of the effects may be influenced by
gene–gene interactions, for example estrogen receptor α
(ERα) gene and COLIA1 polymorphisms. Moreover, ade-
quate daily calcium and/or vitamin D intake can mask or
unmask a ‘physiological’ reduction in activity of the recep-
tor associated with specific VDR gene polymorphisms.
Understanding gene action, gene–gene and gene–envi-
ronment interactions could improve both regimens and
strategies for optimal individualized therapy.
Genetics of osteoporosis
Presentations on the genetics of OA were given by L
Masi, L Gennari and A Falchetti (Department of Internal
Medicine, University of Florence, Florence, Italy).
The estrogen response model and male osteoporosis
L Masi discussed the estrogen response model and male
OP was discussed by L Gennari. Estrogen response rep-
resents the endpoint of an intricate network constituted by
several genes, with multiple polymorphisms, encoding
receptors and enzymes, with the intervention of co-activat-
ing and co-repressing factors. Furthermore, this network is
complicated by all the possible interactions that all these
components might have in various tissues. Thus, the final
response could be dependent on a sort of physiological
mosaicism.
Extragonadal estrogen biosynthesis has different features
than ovarian. Locally synthesized estrogen predominantly
acts at a local level in a paracrine or intracrine fashion. The
aromatase gene (CYP19) encodes a specific enzyme that,
at peripheral levels (particularly bone and adipose tissue),
converts androgenic precursors into estrogen molecules.
The observation [17,18] of marked bone phenotype in
men with mutation of either the ERα or  CYP19 genes
leads to the conclusion that local estrogen production in
bone cells plays an important role in the maintenance of
bone mineralization and the prevention of OP in both
women and men. In fact, dinucleotide polymorphism of
ERα gene, genetic variants of CYP19 gene may generally
alter the estrogen response at several sites. A polymor-
phic repeat of CYP19 has been recently associated with
bone loss, risk of fractures and risk of breast cancer
[19,20]. Interestingly, fibroblasts from subjects with the
CYP19 genotype associated with high BMD and low frac-
ture risk synthesize a higher amount of estradiol than
fibroblasts with the opposite genotype. Such findings
might also lead to new modalities of therapy in the future.
Little is known about the pathogenesis of male OP. The
estrogen response uses mechanisms that might account
for bone loss in males. Although common genetic variants
of  ERα,  CYP19 and other genes might act along with
environmental factors to determine OP in men, different
genetic determinants might explain the site-specific skele-
tal diversity of size and bone-loss rate in males with
respect to females. Candidate genes for male OP are329
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mostly shared with women: VDR, COLIA1, CYP19, IGF-1
(insulin-like growth factor 1), IL-6, ERα and AR (androgen
receptor). Larger studies are needed to confirm prelimi-
nary findings.
Genetics of familial osteoporosis
The presentation by A Falchetti discussed how, although
many diseases run in families (i.e. they cluster), it is not
enough to conclude genetic factors are involved. In fact, it
is entirely possible that a disease having no genetic etiol-
ogy could also show evidence of familial aggregation or
clustering due to a shared exposure or culturally transmit-
ted risk factor. The genetic contribution accounts for peak
of bone mass, the positive relationship between maternal
history of fracture and recurrence risk, the higher risk of
children having low BMD if their parents have low BMD,
and variation of bone geometric measures, such as hip
axis length.
Findings on a shared genetic contribution to BMD in
males and females have been controversial. Many con-
founding factors exist for family-based studies, such as
environmental factors acting differently over the course of
the lifespan, the comparison of individuals of widely differ-
ent ages and year-of-birth cohorts and familiarity in lifestyle
choices. The classic linkage approach is less suitable for
identifying all the OP genes, because of both the multi-
genic nature of disease and the difficulty in collecting
multigenerational pedigrees. Most data, from sib-pair
analyses, conflict and there are ‘arbitrary’ differences both
in study design and in statistical approaches. Ideal prereq-
uisites for investigating the genetics of familial OP would
be the collection of extremely large numbers of families,
the creation of adequate nonparametric linkage analysis
packages, and the consideration of particular environmen-
tal factors not commonly experienced in many studies.
Research on familial OP still suffers at least four major
problems: first, the lack of a clear definition of phenotype
(e.g. BMD, Z-score, fractures); second, the difficulty in
obtaining multigenerational kindreds (late onset disease);
third, the lack of adequate statistical approaches to multi-
factorial diseases; and fourth, the genetic effect on bone
may be gender-, age- and site-specific.
Phenotype assessment is a crucial issue in gene mapping
of complex traits and its misclassification can lead to spu-
rious results of genetic analysis. The lack of a standard-
ized definition of a complex trait phenotype may hamper
the comparison of genetic studies. An algorithm should be
proposed for classifying an ‘osteoporotic’ phenotype in
family members of probands with low BMD, similar to the
one used for differentiating asthma from chronic obstruc-
tive pulmonary disease. Particularly, restriction of selection
criteria, narrowing the recruitment of families, can provide
a more homogenous population for family-based studies.
Genetics of bone development in animal
models
EF Wagner (Research Institute of Molecular Pathology
(IMP), Wien, Austria) discussed the genetics of bone
development in animal models.
Fos proteins are transcription factors belonging to the
AP-1 complex and are involved in many important physio-
logical cell processes. In particular, c-Fos is a key regula-
tor of bone development. Mice lacking c-Fos are
osteopetrotic because of a block in osteoclast differentia-
tion that results in changes in osteoclastic bone resorption
activity. In contrast, transgenic mice overexpressing Fra-1
(a c-Fos- related protein) develop bone osteosclerosis as
a result of an increase in bone formation due to a differen-
tiation defect in osteoblasts, even if the Fra-1-transgenic
osteoclasts are hyperactive in vitro. Moreover, gain of
function of c-Fos, in an in vivo analysis, determines the
transformation of osteoblasts and the occurrence of
osteosarcomas. Interestingly, experiments on knock-in
mice expressing Fra-1 in place of c-Fos demonstrated that
Fra-1 is able to rescue the c-Fos-dependent functions in
bone development in a gene-dosage dependent manner,
but not the in vitro target gene expression. Such systems
will be useful for detecting new c-Fos target genes using
the microarray approach.
Molecular mechanisms underlying the role of Fos proteins
are necessary for regulating bone cell development and dif-
ferentiation. In osteoclasts, inactivation of c-Jun (the molec-
ular partner of c-Fos in activating transcription) causes
inefficient cell differentiation, suggesting an important role
for Jun proteins in skeletal development and differentiation.
Moreover, chondrocyte-specific c-Jun inactivation in
col2A1-cre-transgenic mice results in severe scoliosis due
to failure of intervertebral disk formation and abnormal ver-
tebral arch development. This indicates a role for c-Jun in
regulating sclerotomal differentiation.
Genetics of familial osteochondrodysplasias
The genetics of familial osteochondrodysplasias were dis-
cussed by J Korkko (Tulane University Health Sciences
Center, Center for Gene Therapy and Department of Med-
icine, New Orleans, LA, USA).
Osteochondrodysplasias, an extremely heterogeneous
group of disorders, exhibit abnormalities both in cartilage
and bone growth and development. More than 230 differ-
ent osteochondrodysplasias have been classified. As a
group of disorders they are quite common, with a signifi-
cant socio-medical impact. A wide phenotypic spectrum
characterizes familial forms. Genetic bases of these disor-
ders encompass recurrent mutations of FGFR3 (the gene
encoding fibroblast growth factor receptor 3) in achon-
droplasia, and essentially private mutation in a large gene
such as COL2A1. The search for COL2A1 mutations is330
time-consuming and expensive. Mutation detection never
reaches 100%, even in patients with a classic phenotype.
Linkage studies of large families are very useful for these
disorders and recent advances in DNA microarray tech-
nology represent a promising methodological approach to
reveal affected pathways or defective genes.
Pharmacogenomics in osteoarticular disorders
The presentation on pharmacogenomics in osteoarticular
disorders was given by ML Brandi (Department of Internal
Medicine, University of Florence, Italy).
Pharmacogenomics could drastically change the face and
the outcome of drug development, reducing the number of
people that must be included in clinical trials (in other
words, only people known to be responders would be
included in the study). Polymorphisms could be used as
predictors of drug response, facilitating the drug design
process. In the case of complex disorders, the ‘one drug
fits all’ attitude allocates patients to empirical trial-and-
error periods before acceptable regimens can be decided.
Few examples concerning pharmacogenomics and
osteoarticular disorders are actually available. It is known
that healthy premenopausal women exhibit a different
response to calcitriol according to the specific genotype
at the 3′ end of VDR, and the magnitude of the estrogen
response differs according to which polymorphisms of
ERα and CYP19 genes they have. Genetic variants might
be present in a drug’s target receptor or might produce
adverse reactions to the drug or altered drug metabolism.
In fact, pharmacotherapy can be influenced by three
general pharmacogenetic mechanisms: first, polymor-
phisms of genes associated with altered drug metabolism;
second, genetic variants that produce an unexpected and
undesirable drug reaction; third, genetic variation in a drug
target that alters the clinical response and frequency of
side effects. Data are available for asthma, cancer and
psychiatric disorders, while little exists concerning drug
effects in osteoarticular disorders. Pharmacogenomics
represents the promise of treating people effectively and
of creating ‘tailored’ individual therapy.
Conclusion
Current problems
To date, most of the reports on population-based genetic
analysis of OP consider single candidate gene polymor-
phisms, sometimes limited to a single polymorphism. The
candidate gene polymorphism approach suffers from con-
founding factors such as selection bias, differences
among ethnic groups, inadequate sample size, environ-
mental factors and linkage disequilibrium; prudence is
mandatory in interpreting results from such studies. More-
over, correlation between DNA sequence variants and
functional variants does not exist or has not been investi-
gated or reported, importantly decreasing the statistical
and biological power of such observations.
Potential solutions
Future efforts will identify all polymorphisms across the
VDR and COLIA1 genes, as well as in other/new candi-
date genes for OP and OA. Definition of the haplotype
patterns will help us understand the pathophysiological
role that the polymorphisms themselves might exhibit in
the acquisition of specific bone/articular joint phenotypes.
Thus, both multiple intragenic polymorphisms and multi-
genic complex haplotypes have to be analyzed in defining
any genetic susceptibility to these disorders. Larger popu-
lation studies have to be performed, taking these
approaches into account. Environmental factors, particu-
larly nutrients, have to be accurately evaluated together
with complex genotyping, in order to weight their impor-
tance in masking or unmasking functional variants with
respect to specific genetic background in order to create
more effective preventive strategies for OP and OA. Accu-
rate standardized phenotype definitions are needed to add
a more powerful statistical value to family-based studies.
Probably, this will focus on subsets of kindreds more homo-
geneously defined, but adequate nonparametric linkage
analysis packages must be developed. To date no general
consensus exists on the parameters that ought to be con-
sidered for phenotyping generalized OA and familial OP.
Hopes for the future
Comparative genetics will add information on potentially
interesting genes in humans once quantitative trait loci
have been identified in animal models. Great results are
expected from development of new DNA microarray and
bioinformatic technologies, not only for gene variant
detection, but also for proteomic and metabolomic
aspects of the pathogenesis of OP and OA. These results
will provide new opportunities for identifying people at risk
of developing osteoarticular disorders. Data generated will
enable us to develop new, tailored therapies for testing
with newly designed clinical trials that involve more care-
fully selected individuals, creating the opportunity of avoid-
ing or reducing severe side effects.
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